Pilot Study of T—Tone (Dekofcyn)
in Bronchiectasis
Dr. Arun B. Deshpande
M. D. ( Chest ), T. D. D., D. D. V. ( CPS ), D. V. and D. ( Bom ), Chest Physician, E. S. I. S. Aundh Hospital, Pune 411 027
Dr. V. M. Wagh
M, D. ( Medicine ), Physician, Poona, Present address : Jersey City Medical Centre ( College ), New Jersey 07018 ( U. S. A. )
Paper presented at World Congress on Asthma, Bronchitis and Conditions allied, at Vigyan Bhavan, New Delhi, November, 1974.
Maharashtra Medical Journal, Vol. XXIII : Na. 12, March 1977
Bronchiectasis is a common suppurative lung disease that we come across in Chest Practice. A cough with foul smelling mucopurulent copious amount of expectoration is a characteristic symptom of this disease. The amount of production of sputum depends upon severity and the extent of the disease and also the segments of lungs involved. Medical management of Bronchiectasis is a perplexing problem to the treating physician, especially the symptom of COUGH WITH EXPECTORATION of mucopurulent foul smelling sputum.
The results of medical management of Bronchiectasis with usual treatment, viz : Antibiotics, Bronchidilators, Expectorants, Postural Drainage are unpredictable, due to
- lack of financial and medical resources,
- side effects of the drug,
- emergence of bacterial resistance,
- spread of the disease due to ‘ Spill-over of sputum.’
This has prompted us to carry out the present study, to reduce the production of sputum to minimal or nil from the respiratory tract.
MATERIAL AND METHODS
45 adult cases of Bronchiectasis were included in this series. The diagnosis of Bronchiectasis was based on :
- Symptomatology,
- X-ray of the chest PA view,
- Sputum examination for AFB x gram staining,
- Culture and sensitivity tests,
- Confirmation by Bronchography.
T-Tone ( Alarsin ) will be marketed hereafter as ‘ DEKOFCYN
PLAN OF TRIAL :
Out of 45 cases, 15 were taken as control group and they were treated with standard drug regimen, viz :
- Control Group : Antibiotics ( suitable ), Bronchodilators, Expectorants, Postural drainage, Breathing exercises, etc.
Remaining 30 cases were sub-divided into two groups ;
- Trial groups
- Antibiotics, T-Tone (Dekofcyn), Postural drainage.
- T- Tone ( Dekofcyn) alone, Postural drainage.
|
T- Tone ( Alarsin ) tablets composition : |
|
| Talispatra Compound (Taxus buccata) | 175 mgm |
| Praval Bhasma (Corallium rubrum) | 82 mgm |
| Abhrak Bhasma (Mica) | 6.5 mgm |
| Suvarnamakshikam (Iron Sulphar Comp.) | 25 mgm |
| Vasantmalini Suvarna | 1.5mgm |
Actions of T- Tone (Dekofcyn)
- Antitussive and antispasmodic property,
- Reduces sputum production from respiratory tract,
- Raises the immunity, hence it increases general as well as local resistance against infection,
- Does not depress respiratory centre.
Doses : Two tablets i. e. 520 mgm three times a day for 15 days. Then one tablet (260 mgm ) three times daily as maintenance dose.
Duration of therapy : Four months.
Side effects : Nil.
MECHANISM OF ACTION :
The decrease in the production of broncheal secretions is due to Talispatra Compound and Praval Bhasma.
Exact action by which it occurs is not known. But according to trio theory of Ayurveda of Cough, Vata and Pitta, Pitta component is responsible for ihis action. Pitta means secretions and thus this drug decreases the production of abnormal secretions in the respiratory tract (Broncheal tree).
Follow-up study was continued for four months pertaining to quality of sputum.
RESULTS :
| Decrease in the production of sputum (expectoration) | |||||||
| No of cases | Groups | No of cases | 2weeks | 4week | 6weeks | 4weeks | % |
| 45 | Control Group | 15 | 3 | 2 | 2 | 7 | 46% |
| Trial Group A | 15 | 8 | 3 | 2 | 13 | 86% | |
| Trial Group B | 15 | 2 | 1 | Nil | 4 | 26% | |
Excellent results in Trial Group (A) in two weeks and at four months.
Maharashtra Medical Journal, Vol. XXIII: No. 12, March 1977
CONCLUSIONS :
- T. Tone (Dekofcyn) acts as an adjuvant along with appropriate antibiotics which gives excellent results in Bronchiectasis as compared with other regimen.
- T. Tone (Dekofcyn), an indigenous drug decreases production of sputum from respiratory tract in Bronchiectasis, which in turn
- prevents ‘further spill-over’ of the disease to the other parts of the lungs,
- reduces chances of developing emergence of bacterial resistance,
- diminishes foul smelling, which is beneficial to the patient and his relatives.
- Subjective feelings of well-being, gain in weight, increased appetite, undisturbed sleep, without any side effects whatsoever.
INDICATIONS :
We suggest the following indications of this indigenous drug in Bronchiectasis :
- as an adjuvant to appropriate antibiotics in routine treatment of Bronchiectasis;
- invitrate cases of Bronchiectasis which are recalcitrant to usual line of treatment;
- cases of Bronchiectasis which are unsuitable for surgical treatment;
- those who refuse surgery.
ACKNOWLEDGEMENT :
We are thankful to Alarsin Pharmaceuticals, Bombay-23, for liberal supply of T-Tone (Dekofcyn) tablets for the present study.
We are also thankful to Mr. Vilas A. Mohadikar for the help he has extended from time to time to conduct this study.
References :
- Adams, R. and Churchil E. D. : Bacteriological considerations in the therapy of chronic supp. bronchitis and bronchiectasis.
- American Review : Respiratory diseases. P. 82, 743, 1968.
- Indigenous drugs of India by Col. Sir R. N. Chopra, 2nd Edition, Pages 461, 535, 526, 660.
- Corwin Hinshaw : Diseases of Chest, Third Edition, W. R. Sannders Co. Philadelphia and London 1964, P. 22, 225.
- Indian Materia Medica by Dr. K. M. Nadkarni, 3rd Edition P. 3, 1197, Volume One and P. 34, 125, 157, 67 Volume Two.
- Price : Text book of the practice of Medicine, 7th Edition, Oxford Uni. Press, London, P. 1176.
Maharashtra Medical Journal, Vol. XXIII: No. 12, March 1977